Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Navigating the Evolving Head and Neck Cancer Treatment Continuum

Clinical Thought

Experts answer your questions related to the program, “Expert Guidance on Navigating the Evolving Head and Neck Cancer Treatment Continuum: What Matters Now and How to Apply It in Practice.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program. 

Released: July 01, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Johnson & Johnson and Merck Sharp & Dohme LLC.

Johnson & Johnson

Merck Sharp & Dohme LLC

Target Audience

This activity is intended for head and neck surgeons, oncologists, nurse practitioners (NPs), physician assistants (PAs), nurses, pharmacists, and other healthcare professionals involved in the multidisciplinary care of patients with HNSCC and related head and neck malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret current and emerging clinical evidence in HNSCC and distinguish established standards from evolving investigational approaches

  • Apply guideline-informed treatment strategies across resectable, recurrent, and metastatic HNSCC settings

  • Individualize treatment selection and sequencing based on clinical context, biologic risk, and likely mechanisms of resistance

  • Anticipate, recognize, and manage treatment-related and immune-related adverse events to support patient safety, treatment continuity, and quality of life

  • Incorporate multidisciplinary and supportive care strategies into treatment planning to improve functional and patient-centered outcomes

Financial Disclosures

Primary Author

Barbara Burtness, MD: consultant/advisor/speaker: Bicara, Genmab, GSK, Johnson & Johnson, Merck, One Carbon, Rakuten, Takeda; data and safety monitoring board: Merus.

Robert Haddad, MD: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genmab, Incyte, Johnson & Johnson, Merck, Merus, Nanobiotix; researcher: Aveo, GSK, Incyte, Merck, Merus.

Ari J. Rosenberg, MD: consultant/advisor/speaker: Adela, Astellas, Bicara, Coherus Biosciences, Corbus, Eisai, EMD Serono, Exelixis, Galectin, GeoVax, Janssen, Nanobiotix, Novartis, Privo Technologies, RAPT Therapeutics, Regeneron, Summit, Vaccitech.